Food and Drug Administration (FDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Food and Drug Administration (FDA) sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Food and Drug Administration (FDA): 23 sponsored US clinical trials, 3 recruiting.
Food and Drug Administration (FDA) sponsors 23 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 20 completed. 0 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Laser in Situ Keratomileusis, with 1 trials.
Top-decile sponsor footprint
Food and Drug Administration (FDA) ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults
NCT07176208
Adaptive Optics Imaging of Outer Retinal Diseases
NCT05355415
Adaptive Optics Retinal Imaging
NCT05370287
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
NCT06192589
Electrophysiological Effects of Potential QT Prolonging Drugs
NCT05716854
Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation
NCT05470465
Human Perception on Medical Extended Reality Devices
NCT05479019
Assessing Variability of the Ventilatory Response to Duffin's Rebreathing Procedure
NCT05168501
Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone
NCT04764630
Bioequivalence Study of Tacrolimus in Healthy Volunteers
NCT04725682
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
NCT04310579
Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration
NCT04397445
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
NCT04183491
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists
NCT04183192
Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors
NCT04189484
Assessment of the Human Systemic Absorption of Sunscreen Ingredients
NCT03582215
Characterization of Epilepsy Patients BEEP 2b
NCT02707965
Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
NCT03100838
CiPA Phase 1 ECG Biomarker Validation Study
NCT03070470
A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects
NCT02821338
Behavioral Pharmacology Associated With Cigar Smoking
NCT02218840
Patient Reported Outcomes With LASIK: PROWL-2
NCT01655420
Patient-Reported Outcomes With LASIK:PROWL-1
NCT01526291
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
What is open in the Food and Drug Administration (FDA) pipeline
3 recruiting of 23 indexed (13% open); 20 completed (87%).
Phase mix: 0 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Laser in Situ Keratomileusis (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Food and Drug Administration (FDA): open-pipeline peers nationwide
Peers matched on 23 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Food and Drug Administration (FDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Loyola University · 13% recruiting · 92 trials
- VA Greater Los Angeles Healthcare System · 13% recruiting · 23 trials
- Intermountain Health Care · 13% recruiting · 85 trials
- MetroHealth Medical Center · 13% recruiting · 76 trials
Related
What to do with this Food and Drug Administration (FDA) page
23 registered trials is a research-attention snapshot, not an endorsement of Food and Drug Administration (FDA) or any single study.
- 3 of Food and Drug Administration (FDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Laser in Situ Keratomileusis is the condition Food and Drug Administration (FDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Laser in Situ Keratomileusis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Food and Drug Administration (FDA) pipeline card: 23 registered trials from official public datasets.Report a data error.